Главная/BSX

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze BSX in workspace
BSXNYSE/health care

Boston Scientific Corporation

$44.65Down-0,12 (-0,27%)
Research reviewed: 12 июл. 2026 г., 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Boston Scientific Corporation operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
45,34
Haut
45,43
Bas
44,36
Capitalisation
66,37 Md
Ratio C/B
18.68
Plus haut sur 52 semaines
--
Dividende
--
Dividende trimestriel
--

3-month price context

График показывает недавний 3-месячный тренд, чтобы пользователи могли понять краткосрочную структуру перед открытием полного рабочего кабинета.

Investment thesis

Base case
FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. The base case remains conditional on regulatory and clinical risk staying manageable.
Bull case
FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand. WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications. A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.
Bear case
Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms. Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio. Large rivals and new technologies can pressure pricing, physician loyalty and market share.
Thesis invalidation
Reassess the thesis if trial outcomes, approval delays or safety signals can slow adoption of important growth platforms.

Key catalysts

  • Pulsed-field ablation

    FARAPULSE adoption can expand electrophysiology procedure share and associated catheter demand.

  • Structural-heart adoption

    WATCHMAN and related structural-heart platforms can benefit from broader physician adoption and indications.

  • New-product pipeline

    A broad cadence of launches across cardiology, endoscopy and urology can sustain above-market procedure growth.

Principal risks

  • Regulatory and clinical risk

    Trial outcomes, approval delays or safety signals can slow adoption of important growth platforms.

  • Portfolio integration

    Acquisitions can create integration costs, leverage and execution demands across a rapidly expanding portfolio.

  • Device competition

    Large rivals and new technologies can pressure pricing, physician loyalty and market share.

Latest earnings research

Q1 2026

Boston Scientific's first-quarter 2026 update reflected broad organic growth across cardiovascular and MedSurg franchises, continued product-launch momentum and integration activity while management maintained its growth outlook.

Valuation interpretation

  • A growth premium depends on durable procedure expansion and multiple platforms contributing rather than reliance on one launch cycle.
  • Pipeline optionality should be discounted for clinical, reimbursement and acquisition-integration risk.

Peer research

ABTISRGSYK

Recent news

StockStory · il y a 16 heures

1 Stock Under $50 to Keep an Eye On and 2 We Brush Off

Insider Monkey · hier

Boston Scientific Corporation (BSX) Is A Stock To Buy According To D. E. Shaw

Zacks · il y a 4 jours

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

Trefis · il y a 5 jours

The Wide Chasm Priced Into Boston Scientific Stock

MedTech Dive · il y a 5 jours

J&J wins FDA approval for dual-energy ablation catheter

Motley Fool · il y a 5 jours

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock

Data and research sources

Research updated: 12 июл. 2026 г., 00:00 UTC
3 verified sources
Q1 2026 Earnings Release and Financial ResultsBoston Scientific Corporation · earningsVerified

Fetched: 12.07.2026, 0:00:00 UTC

Published: 22.04.2026, 00:00:00

Open original source
Boston Scientific Corporation Investor RelationsBoston Scientific Corporation · companyVerified

Fetched: 12.07.2026, 0:00:00 UTC

Open original source
Boston Scientific SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.07.2026, 0:00:00 UTC

Published: 22.04.2026, 00:00:00

Open original source

Continue in the research workspace

Keep BSX in context, run a multi-agent analysis, and monitor thesis changes.

Analyze BSX free

Изучить всю систему анализа

У каждого этапа своя задача и проверяемый результат.

Методология исследованияЧитать обзоры рынкаИзучить акции

Continue researching this stock

Market Analyst

Reads price structure, trend strength, and market posture before thesis formation.

Fundamentals Analyst

Owns business quality, earnings structure, and financial health.

News Analyst

Tracks what just happened and whether it actually changes the thesis.

Risk Manager

Sets the final risk classification and action boundaries after the risk debate.